Release No 6/2010 Affitech A/S announces Annual Report for 2009 Copenhagen and Oslo, April 9th, 2010 Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced the publication of its Annual Report for 2009. The Report summarises specific goals that the Company has set itself for undertaking the next phase of its transformation into an internationally competitive antibody therapeutics company. The Annual Report can be downloaded from the Company's website at www.affitech.com -------------------------------------------------------------------------------- | For more information please contact: | -------------------------------------------------------------------------------- | | | Affitech A/S: | | | | Randi Krogsgaard | | Tel # +45 2320 1001 | -------------------------------------------------------------------------------- About Affitech A/S Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of therapeutic antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech A/S's premier technology platform for the isolation of lead antibodies to cell surface targets. Several of the Company's proprietary drug candidates were generated by CBAS™. Further information is available at www.affitech.com. - ends -